-
Product Insights
Cutaneous T-Cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Cutaneous T-Cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Cutaneous T-Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cutaneous T-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Thyroid Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Thyroid Cancer - Drugs In Development, 2023’, provides an overview of the Thyroid Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – HM-01 in Chemotherapy Induced Peripheral Neuropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HM-01 in Chemotherapy Induced Peripheral Neuropathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HM-01 in Chemotherapy Induced Peripheral Neuropathy Drug Details: HM-01 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efzofitimod in Pulmonary Sarcoidosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Efzofitimod in Pulmonary Sarcoidosis Drug Details: efzofitimod (ATYR-1923) is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – VAX-24 in Streptococcal Pneumonia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VAX-24 in Streptococcal Pneumonia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.VAX-24 in Streptococcal Pneumonia Drug Details:VAX-24 is under development for the prevention of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dihydroergotamine Mesylate (Dhe) in Migraine
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dihydroergotamine Mesylate (Dhe) in Migraine report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Dihydroergotamine Mesylate (Dhe) in MigraineDrug Details:Dihydroergotamine mesylate is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (IO-102 + IO-103) in Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (IO-102 + IO-103) in Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (IO-102 + IO-103) in Head...
-
Sector Analysis
Contract Pharmaceutical Dose Manufacturing Industry – Composition, Size, Market Share and Outlook, 2023 Edition
Contract Pharmaceutical Dose Manufacturing Industry Overview The total dose CMO contract revenue in 2022 represented significant growth over 2021 revenue. The growth rate was the highest recorded since 2011 for commercial contract dose manufacturing revenues, and surprisingly adds to the strong growth experienced in 2021, despite demand for COVID-19 vaccines and therapies waning in 2022. The Contract Pharmaceutical Dose Manufacturing Industry report is a comprehensive look at the finished dose contract manufacturing landscape in 2023. It includes an analysis of...
-
Company Profile
BridgeBio Pharma Inc – Company Profile
BridgeBio Pharma Inc (BridgeBio) is a commercial-stage biopharmaceutical company that develops drugs for genetic diseases and cancer. The company’s pipeline products include precision cardiorenal, mendelian, precision oncology and gene therapy. Its precision cardiorenal and mendelian drugs include acoramidis, encaleret, fosdenopterin, low-dose infigratinib, BBP-418 and BBP-671. BridgeBio’s precision oncology and gene therapy drugs include high-dose infigratinib, BBO-8520, BBP-398, PI3Kα, BBP-954, Pan-KRAS inhibitor, BBP-812, BBP-631 and AAV gene therapy. The company's brands include TRUSELTIQ and NULIBRY. It works in partnership with academic...
Add to Basket